Omega-3 is one of the few supplement categories where the mechanism is genuinely uncontroversial: DHA is a structural component of neuronal membranes, and the brain is one of the most DHA-dense tissues in the body. What's less settled is exactly how supplementing with EPA and DHA translates into measurable cognitive benefit, and at what dose. A large 2025 dose-response meta-analysis gives the clearest picture yet — and a smaller but important body of genetic and blood-marker research explains why that picture looks different from person to person.
The evidence
The review pooled 58 randomized controlled trials and modelled omega-3's effect on cognition per 2,000mg/day increment of intake.1 Several domains showed statistically real, if modest, improvement: attention, language, global cognitive ability, primary memory, visuospatial function and perceptual speed all moved in the right direction. The strongest, moderate-certainty signals were in memory and visuospatial function; the rest were rated low certainty. This is the headline result most coverage of omega-3 and the brain reaches for, and it's a fair one — but it's an average across everyone in 58 trials, and averages hide who actually responded.
The part that complicates the story
More omega-3 did not mean a straight-line better result. The dose-response relationship was non-linear for some outcomes — episodic memory showed a U-shaped curve (an initial dip before improving at higher intakes), and global cognitive ability showed an inverted U (improving, then declining, as dose kept climbing). The honest summary from the researchers themselves: omega-3 supplementation may lead to a modest improvement in cognitive function, with the emphasis on modest, and a clear call for longer, better-controlled trials before treating the effect as settled.
A modest average effect can still mean a strong effect for some people and none at all for others — and for omega-3, we now have a decent idea of why.
Why the same dose doesn't work the same way for everyone: APOE4
The clearest source of that variation is a gene almost everyone has heard of in the context of Alzheimer's risk: APOE. Most people carry the ε3/ε3 version. A smaller group carries at least one ε4 allele, which is associated with higher lifetime risk of Alzheimer's disease and, it turns out, a measurably different response to DHA supplementation.
The clearest data on this comes from a re-analysis of the Alzheimer's Disease Cooperative Study's DHA trial — a randomized, double-blind, placebo-controlled study that gave 275 older adults either 2,000mg/day of DHA or placebo for 18 months, with a subset undergoing brain MRI.2 Everyone took the same capsules. Not everyone's blood, or brain, responded the same way.
The gap wasn't confined to blood chemistry. On brain MRI, ε2/ε3 carriers showed 10% less decline in left hippocampal volume than ε4/ε4 carriers over the same 18 months (p<0.001), and a similar pattern held for the right hippocampus. The researchers' interpretation was direct: in ε4/ε4 carriers, DHA supplementation raised blood DHA less, delivered less of it to the brain, and produced less protection for a brain region central to memory.
| APOE genotype | Plasma DHA response to 2,000mg/day DHA (18 months) | Hippocampal volume change vs. ε4/ε4 |
|---|---|---|
| ε2/ε3 | 38% greater increase in DHA/AA ratio | 10% less left-hippocampal decline (p<0.001) |
| ε3/ε3 (most common) | 23% greater increase in DHA/AA ratio | Not significantly different |
| ε4/ε4 | Smallest increase (reference group) | Greatest decline (reference group) |
This doesn't mean DHA is pointless for ε4 carriers — the trial wasn't designed or powered to answer that definitively, and other work on APOE and omega-3 metabolism is still being worked out.3 It means the same label dose can produce a meaningfully different result depending on genotype most people have never checked, which is a more useful and more honest way to think about "why didn't I notice anything" than assuming the supplement failed.
Can a blood test tell you if it's actually working?
Genotype is one variable. Absorption, diet, and baseline levels are others — which is why some researchers argue the more practical, actionable number isn't your genes but your omega-3 index: the percentage of EPA and DHA in your red blood cell membranes, measured from a simple blood draw.
The best population-level evidence for why that number might matter comes from the Framingham Heart Study, which measured red blood cell omega-3 levels and brain MRI/cognitive testing in 2,183 dementia- and stroke-free adults with an average age of 46.4 A higher omega-3 index was associated with larger hippocampal volume and better abstract reasoning scores. Interestingly, the pattern split by genotype in a way that echoes the APOE trial above: DHA and overall omega-3 index tracked with hippocampal volume mainly in people without an ε4 allele, while in ε4 carriers it was specifically EPA — not DHA — that associated with better reasoning performance, and higher omega-3 levels that corresponded with less white-matter damage.
Put together, these two studies suggest a more nuanced, and more testable, picture than "take omega-3 for your brain": the ratio of EPA to DHA that matters may depend on your genotype, and whether a given dose is doing anything measurable in your body is something you can actually check — via an omega-3 index test — rather than assume from the label.
What this means for dosing
The trials driving the strongest cognitive signals in the 2025 meta-analysis generally used higher combined EPA+DHA intakes than a typical maintenance serving, and the APOE and Framingham data above used DHA doses (2,000mg/day) well above most consumer products. Proco Omega-3 is dosed at 180mg EPA + 120mg DHA per serving — a studied, disclosed maintenance-range dose aimed at closing a dietary gap and supporting normal brain and heart function, not replicating the higher-dose cognitive-trial protocols in this review. We'd rather be precise about that than let the word "brain support" imply more than the label dose delivers.
If you want to know whether your own supplementation — at whatever dose — is actually raising your blood omega-3 levels, an omega-3 index test is a legitimate, inexpensive way to check that directly, instead of guessing from how you feel. It won't tell you your APOE status, and a good index score doesn't guarantee a cognitive effect on its own terms, per the Framingham findings above. But it answers a narrower, more honest question: is the supplement doing the one thing we can actually measure.
Bottom line
The biological case for omega-3 and brain health is strong; the cognitive-performance evidence is real but modest, dose-dependent in a non-obvious way, and still maturing. Genetics adds another layer: APOE ε4 carriers appear to convert supplemental DHA into blood and brain DHA less efficiently than non-carriers, which may partly explain why some people notice more benefit than others at the same dose. None of that changes the practical starting point — take omega-3 for the well-established reasons (filling a dietary gap, supporting normal brain and heart function) rather than expecting a guaranteed, uniform cognitive jump from a standard serving, and treat genotype or an omega-3 index test as ways to refine expectations, not as prerequisites to start.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- A systematic review and dose-response meta-analysis of omega-3 supplementation on cognitive function. Scientific Reports, 2025. nature.com
- Tomaszewski N, He X, Solomon V, Lee M, Mack WJ, Quinn JF, Braskie MN, Yassine HN. Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer's Disease Cooperative Study-Sponsored DHA Clinical Trial. Journal of Alzheimer's Disease, 2020;74(3):975-990. pmc.ncbi.nlm.nih.gov
- Effects of APOE4 on omega-3 brain metabolism across the lifespan. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2024. sciencedirect.com
- Satizabal CL, et al. Association of Red Blood Cell Omega-3 Fatty Acids With MRI Markers and Cognitive Function in Midlife: The Framingham Heart Study. Neurology, 2022. neurology.org
Related reading: Omega-3 Dosage Guide: EPA, DHA, and What the Research Says, Omega-3 and Heart Health: Two Major Reviews, Two Different Conclusions, Creatine and the Brain: What the Cognitive Research Actually Shows, and Omega-3 and Adult ADHD: What the Evidence Shows.
Proco Omega-3 delivers 180mg EPA + 120mg DHA per serving, third-party tested every batch. Shop Omega-3 →